ISS Recommends Aptose Biosciences Shareholders Vote 'FOR' Hanmi Pharmaceutical Acquisition
APTOF has more than doubled off its 52-week low of $0.636 on light trading volume (0.1× avg).
Summary
Aptose Biosciences announced that ISS recommends shareholders vote 'FOR' the acquisition by Hanmi Pharmaceutical, a key step towards closing the C$2.41 per share cash deal.
Key Events · M&A and Partnerships · APTOF
-
ISS Recommends Acquisition Approval
Institutional Shareholder Services (ISS) has recommended that Aptose shareholders vote 'FOR' the special resolution to approve the Plan of Arrangement with Hanmi Pharmaceutical Co. Ltd.
-
Acquisition Terms Confirmed
Upon completion, shareholders will receive C$2.41 in cash per common share, representing a 28% premium over the 30-day VWAP of C$1.88 on the TSX as of November 19, 2025.
-
Shareholder Meeting Reconvened
A special meeting of shareholders to approve the Arrangement and a Continuance (change of incorporation) has been reconvened to March 31, 2026, following a postponement to address SEC comments.
-
Board Unanimously Recommends 'FOR'
Aptose's board of directors unanimously recommends that shareholders vote 'FOR' both the Continuance and the Arrangement Resolution.
Analysis · APTOF · Life Sciences
Institutional Shareholder Services (ISS), a leading independent proxy advisory firm, has recommended that Aptose shareholders approve the proposed Plan of Arrangement with Hanmi Pharmaceutical. This recommendation significantly increases the likelihood of the acquisition closing, as ISS guidance often sways institutional investors. The deal offers C$2.41 in cash per share, representing a 28% premium over the 30-day VWAP as of November 2025, providing liquidity and certainty of value to shareholders. The reconvened shareholder meeting on March 31, 2026, is the next critical step for the transaction's completion.
At the time of this filing, APTOF was trading at $1.64 on OTC in the Life Sciences sector, with a market capitalization of approximately $4.2M. The 52-week trading range was $0.64 to $229.50. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.